

Remarks

Upon entry of the foregoing amendment, claims 94-95, 99-103, 105-107, and 131-146 are pending in the application, with claims 94, 95, 107, and 139 being the independent claims. The pending claims have been amended as agreed with Examiners Vanessa L. Ford and Robert Mondesi during the telephonic interview held on December 11, 2008. The Examiners agreed to consider the claims presented at the interview after final.

Claims 94-95, 99-103, 105-107, and 131-147 have been amended to recite "an immunogenic composition," as discussed in the Interview held on December 11, 2008. Amendments to claims 100-102 are respectfully requested to correct a clerical error in claim dependencies. Clearly, the antecedent basis for "adjuvants" and "immunostimulatory molecules" recited in the claims is found in claim 99.

Based on the following remarks, Applicant respectfully requests that the outstanding rejections be withdrawn.

I. Statements of Substance of Interview

A) Summary of May 20, 2008 Interview

Applicant thanks Examiner Ford for the telephonic interview conducted on May 20, 2008. During the interview, the undersigned attorney and Examiner Ford discussed the captioned application and pending claims. In particular, the Examiner and the undersigned attorney discussed the pending rejections to the claims under 35 U.S.C. § 112, first and second paragraphs. The undersigned attorney agreed to file a reply with the arguments made during the interview. The Reply was filed on June 20, 2008.

B) Summary of December 11, 2008 Interview

Applicant also thanks Examiner Ford and Examiner Mondesi for the telephonic interview conducted on December 11, 2008. During the interview, the undersigned attorney, Examiner Ford, and Examiner Mondesi discussed the captioned application and pending claims. In particular, the pending rejections were discussed in view of proposed claim amendments. Those amendments are presented in this paper.

II. Information Disclosure Statement

The Examiner indicated during the May 11, 2008 interview that she had not received Form PTO/SB/08A and Form PTO/SB/08B for the Seventh Supplemental Information Disclosure Statement filed on October 31, 2007. Applicant resubmitted on June 20, 2008 a copy of Forms PTO/SB/08A and PTO/SB/08B as well as the stamped mailing receipt, indicating that the forms had been correctly submitted on October 31, 2007. Applicant respectfully requests that the forms be signed and dated and returned to Applicant.

III. Rejection of Claims 134 and 142 under 35 U.S.C. § 112, 1st paragraph

Claims 134 and 142 stand rejected under 35 U.S.C. § 112, 1st paragraph, for allegedly failing to comply with the enablement requirement.

During the interview, the Examiners agreed that dependent claims 134 and 142, which recite that the claimed immunogenic composition *further* comprises the *Chlamydia* high molecular weight (HMW) protein, major outer membrane protein (MOMP), or fragments thereof, meet the enablement requirement. Therefore, Applicant respectfully requests that the rejection be withdrawn.

IV. Rejection of Claims 94, 95, 99-103, 105-107, and 131-146 under 35 U.S.C. § 112, 1st paragraph"

Claims 94-95, 99-103, 105-107, and 131-146, previously directed to "vaccine," stand rejected under 35 U.S.C. § 112, 1st paragraph, for allegedly failing to comply with the enablement requirement. Solely to advance prosecution, but not in acquiescence to the Examiner's rejection, Applicant has amended the claims to recite an "immunogenic composition," thereby rendering the rejection relating to "vaccine" moot. The claims also require that an effective amount of the claimed immunogenic composition, upon administration to female mice reduces *Chlamydia trachomatis*-induced infertility.

Accordingly, Applicant respectfully requests that the rejection be withdrawn.

Conclusion

All of the stated grounds of and rejections have been properly traversed, accommodated, or rendered moot. Applicant therefore respectfully requests that the Examiner reconsider all presently outstanding rejections and that they be withdrawn. Applicant believes that a full and complete reply has been made to the outstanding Office Action and, as such, the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Elizabeth J. Haanes, Ph.D.
Attorney for Applicant
Registration No. 42,613

Date: December 18, 2008

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

811382v1